Page last updated: 2024-08-21

diphenylamine and Neurofibroma, Plexiform

diphenylamine has been researched along with Neurofibroma, Plexiform in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Allen, JC; Blakeley, J; Cutter, G; Dombi, E; Edwards, L; Emoto, C; Fisher, MJ; Fukuda, T; Goldman, S; Korf, B; Packer, R; Plotkin, SR; Ratner, N; Robinson, CT; Robison, NJ; Schorry, E; Tonsgard, JH; Vinks, AA; Weiss, BD; Widemann, BC; Wolters, PL	1
Chapuis, N; Hivelin, M; Hubas, A; Lantieri, L; Laurendeau, I; Nusbaum, P; Parfait, B; Pasmant, E; Poulain, L; Varin, J; Vidaud, M; Wolkenstein, P	1

Trials

1 trial(s) available for diphenylamine and Neurofibroma, Plexiform

Article	Year
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 03-01, Volume: 39, Issue:7 Topics: Adolescent; Adult; Benzamides; Diphenylamine; Female; Humans; Magnetic Resonance Imaging; Male; Mitogen-Activated Protein Kinase Kinases; Neurofibroma, Plexiform; Neurofibromatosis 1; Protein Kinase Inhibitors; Time Factors; Treatment Outcome; United States; Young Adult	2021

Article

Year

NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 03-01, Volume: 39, Issue:7

Topics: Adolescent; Adult; Benzamides; Diphenylamine; Female; Humans; Magnetic Resonance Imaging; Male; Mitogen-Activated Protein Kinase Kinases; Neurofibroma, Plexiform; Neurofibromatosis 1; Protein Kinase Inhibitors; Time Factors; Treatment Outcome; United States; Young Adult

2021

Other Studies

1 other study(ies) available for diphenylamine and Neurofibroma, Plexiform

Article	Year
Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. Oncotarget, 2016, Jun-14, Volume: 7, Issue:24 Topics: Antineoplastic Agents; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphenylamine; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Nerve Sheath Neoplasms; Neurofibroma, Plexiform; Neurofibromatosis 1; Neurofibromin 1; Nuclear Proteins; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; ras Proteins; Schwann Cells; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcription Factors	2016

Article

Year

Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.

Oncotarget, 2016, Jun-14, Volume: 7, Issue:24

Topics: Antineoplastic Agents; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphenylamine; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Nerve Sheath Neoplasms; Neurofibroma, Plexiform; Neurofibromatosis 1; Neurofibromin 1; Nuclear Proteins; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; ras Proteins; Schwann Cells; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcription Factors

2016